BUSINESS● LOW1h ago · Oct 23, 2026, 9:05 PM
Corcept Therapeutics plunges 20% on Genmab cancer data
Seeking Alpha Tech · global
Corcept Therapeutics experienced a 20% stock drop following the release of cancer data from Genmab. This financial event indicates market reaction to new medical research affecting pharmaceutical companies.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS8m agoBP, Louisiana reach deal to accelerate Deepwater Horizon paymentsSeeking Alpha TechBUSINESS12m agoElme Communities faces NYSE delisting; OTC trading to begin October 26; shares crashSeeking Alpha Tech